ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
-0.26%
US Tech 100
19,168.00
0.52%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.37515
0.00%
Bitcoin
66,533.07
0.52%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amgen Inc (AMGN)

  7. Amgen Inc (AMGN) News

AMGN

Amgen (AMGN)

Amgen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMGN
DateTimeSourceHeadlineSymbolCompany
06/14/20243:21PMPR Newswire (US)FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASENASDAQ:AMGNAmgen Inc
06/12/20244:23PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMGNAmgen Inc
06/12/20248:00AMPR Newswire (US)AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024NASDAQ:AMGNAmgen Inc
06/05/20243:00PMPR Newswire (US)AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
06/05/20248:00AMPR Newswire (US)AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)NASDAQ:AMGNAmgen Inc
06/04/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/04/20246:22PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
06/03/20244:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
06/03/20243:00PMPR Newswire (US)AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
05/28/20248:00AMPR Newswire (US)AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024NASDAQ:AMGNAmgen Inc
05/19/20244:15PMPR Newswire (US)NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPDNASDAQ:AMGNAmgen Inc
05/16/20245:46PMPR Newswire (US)FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERNASDAQ:AMGNAmgen Inc
05/15/20245:45PMPR Newswire (US)AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024NASDAQ:AMGNAmgen Inc
05/10/20243:02PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMGNAmgen Inc
05/09/20246:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/09/20246:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/09/20246:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/09/20246:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/09/20246:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/09/20246:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
 Showing the most relevant articles for your search:NASDAQ:AMGN

Your Recent History

NYSE
KSO.L
Str PD 7.125 Ibm
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved